Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 8/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884441 | 0.78 | EGFR (0.38) | CSF1RNUDT1EGFRTSHRHTT | |
| SCHEMBL23884623 | 0.73 | TSHR (0.39) | CSF1RNUDT1EGFRTSHRHTT | |
| SCHEMBL21200688 | 0.68 | KDM4E (0.42) | CSF1REGFRMAPTKDM4E | |
| SCHEMBL23906423 | 0.66 | SLC6A4 (0.40) | CSF1RTSHRHTTMAPT | |
| SCHEMBL30251769 | 0.66 | SLC6A4 (0.40) | CSF1RTSHRHTTMAPT | |
| SCHEMBL363322 | 0.66 | CA1 (0.43) | TSHRCA2MAPTKDM4E | |
| SCHEMBL237491 | 0.66 | ALDH1A1 (0.43) | TSHRCA2MAPTKDM4E | |
| SCHEMBL29597336 | 0.66 | ALDH1A1 (0.43) | TSHRCA2MAPTKDM4E | |
| SCHEMBL20442235 | 0.66 | NR4A2 (0.47) | TSHRHTTMAPTKDM4E | |
| SCHEMBL27286640 | 0.65 | EGFR (0.44) | CSF1RNUDT1EGFRTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | CSF1R 2469/4885NUDT1 1590/4885EGFR 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.